疫苗板塊午後拉昇 康希諾大漲超10%
格隆匯5月19日丨疫苗板塊午後快速拉昇,康希諾大漲超10%,西藏藥業漲超7%,復星醫藥漲超3%,沃森生物、智飛生物等翻紅走高。據法新社彙總官方消息來源數據,截至北京時間18日23時30分,全球210個國家或地區至少接種了1500017337劑新冠疫苗,其中近六成集中在中國、美國和印度,依次是中國(4.219億劑)、美國(2.744億劑)和印度(1.844億劑)。由此可見,中國疫苗接種劑次在全球已排第一位。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.